Poor
Not Aligned
Patient Risk:
Moderate
Summary
The provided FDA label excerpts address boxed warnings and geriatric use, but the AI claims primarily concern online purchasing/telehealth/pricing and clinician workflow, which are not supported or contradicted by the supplied LATUDA prescribing information excerpts. Only a small subset of claims are label-relevant; most statements are unsupported given the provided label scope.
Category Scores
Accurate Statements
Elderly patients with dementia-related psychosis treated with antipsychotic drugs (including LATUDA) are at increased risk of death and LATUDA is not approved for dementia-related psychosis.
Supported by Boxed Warning and Sections 5.1 and 8.5.
Antidepressants increase risk of suicidal thoughts and behaviors in pediatric and young adults, and monitoring is recommended.
Supported by Boxed Warning and Section 5.2.
Unsupported Statements
In most cases, lurasidone can only be bought online if a licensed clinician prescribes it after evaluating the patient.
No online purchasing, prescribing process, or telehealth/clinician-evaluation requirements are addressed in the provided label excerpts.
In most cases, lurasidone dispensed online is dispensed by a licensed pharmacy.
Dispensing/online pharmacy licensing is not addressed in the provided label excerpts.
Many legitimate online pharmacies require a valid prescription.
Prescription/online pharmacy practices are not described in the provided label excerpts.
Some telehealth services can lead to a prescription if appropriate.
Telehealth services are not discussed in the provided label excerpts.
Licensed pharmacy dispensing workflows still require a prescription in some countries/regions.
Geographic/legal dispensing requirements are not addressed in the provided label excerpts.
Uploading an existing prescription to a licensed online pharmacy can be a way people obtain lurasidone online for home delivery.
Online delivery logistics are not addressed in the provided label excerpts.
Lurasidone pricing online varies mainly by strength and tablet count.
No pricing information or determinants are provided in the provided label excerpts.
Lurasidone pricing online varies by whether the buyer purchases the brand or generic.
No brand vs generic pricing guidance is provided in the provided label excerpts.
Lurasidone pricing online varies by shipping and pharmacy-specific pricing.
No pricing/shipping information is provided in the provided label excerpts.
Lurasidone pricing online varies by insurance coverage and pharmacy discount programs.
No insurance/discount pricing information is provided in the provided label excerpts.
Generic availability can significantly change the cost of lurasidone.
No generic availability/cost discussion is provided in the provided label excerpts.
When a generic is available, licensed online pharmacies may list generic alongside the brand.
No online listing/formulary/display information is provided in the provided label excerpts.
When a generic is available, generic lurasidone may offer lower prices through insurance copays or cash/discount programs.
No statements regarding cost outcomes via copays/discount programs are provided in the provided label excerpts.
Buying lurasidone from unverified online sellers can result in counterfeit or incorrectly dosed pills.
The provided label excerpts do not discuss counterfeit or dosing errors from online sellers.
Buying lurasidone from unverified online sellers can result in missing or wrong ingredients.
The provided label excerpts do not discuss adulteration/incorrect ingredients from online sellers.
Buying lurasidone from unverified online sellers can lead to delays and lack of recourse if the medication never arrives.
The provided label excerpts do not discuss delivery delays or consumer recourse related to purchasing channels.
Consistently getting the right dose of lurasidone matters for symptom control and side-effect risk.
The provided label excerpts do not include dosing adherence rationale or dose consistency claims.
Usually, starting or changing lurasidone requires clinician involvement.
The provided label excerpts do not address start/change processes in this manner.
Clinicians need to confirm that lurasidone is the right medication for the patient’s diagnosis and symptoms.
No such clinical workflow language is present in the provided label excerpts.
Clinicians need to check for drug interactions and the patient’s medical history when starting or changing lurasidone.
Drug interaction guidance and interaction-checking language are not provided in the supplied excerpts.
Clinicians need to determine the correct starting dose and titration plan for lurasidone.
Dosage selection and titration specifics are not included in the provided label excerpts.
Clinicians need to monitor lurasidone side effects and effectiveness.
The supplied label excerpts do not provide broad monitoring language for side effects/effectiveness (beyond boxed-warning monitoring for suicidal thoughts in pediatric/young adults).
If a patient already has a prescription, ordering lurasidone by mail is typically simpler.
Mail-order logistics are not addressed in the provided label excerpts.
If a patient does not already have a prescription, telehealth or an in-person visit is usually the first step before starting lurasidone.
No guidance on telehealth vs in-person initiation is present in the provided label excerpts.
Contradictions
Important Omissions
Any label-supported details regarding contraindications, dosing/administration instructions, specific warnings/precautions other than the provided excerpts, drug interactions, and adverse reactions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The claims largely concern purchasing channels and pricing rather than LATUDA labeling. While not directly contradicting the boxed warnings shown, the lack of label-grounded medication safety information and the presence of unsupported assertions about counterfeit/incorrect dosing could mislead users about LATUDA safety and proper clinical use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are unrelated to the provided FDA label excerpts and are unsupported (online purchasing/telehealth/pricing workflow statements). Only a minimal subset aligns with the boxed warning/monitoring excerpt content.
Suggested Improvement
Limit statements to what is present in the provided label excerpts (e.g., boxed warning mortality in dementia-related psychosis and suicidal thoughts/behaviors monitoring) and avoid channel/pricing/legal/process assertions unless supported by the prescribing information sections provided.